Τρίτη 12 Απριλίου 2022

Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma

alwin shared this article with you from Inoreader
Via Oncology
Conclusion: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas. (Source: Oncology)
View on the web

Long-Term Cardiovascular Outcomes After Bariatric Surgery in the Medicare Population

alwin shared this article with you from Inoreader

1-s2.0-S0735109722003722-fx1.jpg

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15

Author(s): Amgad Mentias, Ali Aminian, Dalia Youssef, Ambarish Pandey, Venu Menon, Leslie Cho, Steven E. Nissen, Milind Y. Desai

View on the web

Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia

alwin shared this article with you from Inoreader

1-s2.0-S0735109722003862-fx1.jpg

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15

Author(s): Ángel Arenal, Pablo Ávila, Javier Jiménez-Candil, Luis Tercedor, David Calvo, Fernando Arribas, Javier Fernández-Portales, José Luis Merino, Antonio Hernández-Madrid, Francisco J. Fernández-Avilés, Antonio Berruezo

View on the web

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension

alwin shared this article with you from Inoreader

1-s2.0-S073510972200434X-fx1.jpg

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15

Author(s): Yu-Ping Zhou, Yun-Peng Wei, Yin-Jian Yang, Xi-Qi Xu, Tao Wu, Chao Liu, Ke-Yi Mei, Fu-Hua Peng, Hai-Ping Wang, Kai Sun, Jing-Yi Li, Hui-Fang Wang, Meng-Tao Li, Duo-Lao Wang, Qi Miao, Xin Jiang, Zhi-Cheng Jing

View on the web

Principles of Surgery in Head and Neck Cutaneous Melanoma

alwin shared this article with you from Inoreader
Surgical management of head and neck melanoma starts from the primary biopsy of the cutaneous site by a narrow excision with a 1 to 3  mm margins. The margin should include the whole breadth and sufficient depth of the lesion. The key is not to transect the lesion. With the advent of molecular testing, gene expression profiling, and immunotherapies, the surgical management of advanced melanoma has changed. Sentinel lymph node bio psy is an essential armamentarium for T2a and higher staging/greater than 1 mm thick and advance stage disease. Molecular pathogenesis and cancer immunology are recognized in the recent treatment protocols along with surgery in advanced stages of melanoma. (Source: Oral and Maxillofacial Surgery Clinics)
View on the web

Mohs Micrographic Surgery for the Treatment of Cutaneous Melanomas of the Head and Neck

alwin shared this article with you from Inoreader
Surgical excision achieving clear histologic margins remains the mainstay treatment for primary cutaneous melanoma. Tumors of the head and neck, particularly those arising in chronically sun-damaged skin, often demonstrate extensive and asymmetric subclinical extension. Over the decades, this has proven to be a significant problem for tumors arising on the head and neck, as anatomic and functional complexities of these areas have led to suboptimal surgical treatment, yielding unacceptably high rates of local recurrence and persistently positive margins with traditional wide local excision. Patients who undergo Mohs micrographic surgery may have improved survival over those who undergo wide local excision. (Source: Oral and Maxillofacial Surgery Clinics)
View on the web

Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma

alwin shared this article with you from Inoreader
Via Oncology
CONCLUSION: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas.PMID:35405680 | DOI:10.1159/000524500 (Source: Oncology)
View on the web

Αρχειοθήκη ιστολογίου